Protagonist Therapeutics earnings release, August 5, 2026
Protagonist
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ICOTYDE™
First Full Quarter of Commercial Sales with Strong Early Adoption
Rusfertide
NDA under Priority Review for Polycythemia Vera; PDUFA Date in August 2026
Comprehensive
Phase 2b Program with PN-881, an Oral IL-17 Antagonist for Psoriasis, Planned to Initiate Early Q1 2027
Phase
1 Study Initiated with PN-477sc, a Triple GLP1/GIP/GCG Agonist Peptide for Obesity
Cash,
Cash Equivalents and Marketable Securities of $849.5 Million as of June 30, 2026
NEWARK, Calif., August 5, 2026 – Protagonist
Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today reported financial results for the second quarter ended June 30, 2026 and provided a corporate update.
"The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch of ICOTYDE through our strategic partner and accelerating momentum across our internal R&D pipeline. ICOTYDE is quickly becoming a paradigm-shifting oral therapy for patients with moderate-to-severe plaque psoriasis, and rusfertide is approaching an FDA decision that could establish it as a first-in-class erythrocytosis targeted medicine for patients with polycythemia vera,” said Dinesh V. Patel, PhD, President and Chief Executive Officer of Protagonist Therapeutics.
“Equally exciting is the decision to advance our wholly-owned oral IL-17 antagonist PN-881 into a comprehensive Phase 2b psoriasis program, based on the strongly supportive pharmacokinetic results from the Phase 1 study. Behind PN-881, we have a maturing set of diverse assets moving toward clinical studies in obesity, hematology and immunology. These are the results of years of disciplined investment in differentiated science and mark the beginning, not the culmination, of a new phase of value creation as we continue to advance our peptide platform and clinical pipeline.”
Second
Quarter 2026 Recent Developments and Upcoming Milestones
Rusfertide:
Subcutaneous
Injectable Hepcidin Mimetic for Polycythemia Vera (PV)
ICOTYDE™
(Icotrokinra): Oral IL-23 Receptor Antagonist
Wholly-Owned Clinical and Discovery
Programs¹
Additional information provided on slides 24 and 25 in the corporate deck posted to the corporate website as well as in the 8-K filed with the SEC on August 5,
2026
Second Quarter 2026 Financial Results
License and Collaboration Revenue
:
License and collaboration revenue of $213.5 million for second quarter of 2026 consisted primarily of (i) $192.4 million related to proportional recognition of the initial $200.0 million opt-out payment received from Takeda and (ii) $21.1 million for ongoing development services, including post opt-out wind down services, and rusfertide clinical supplies provided by us under the Takeda Collaboration Agreement and other revenues.
License and collaboration revenue of $269.8 million for six months ended June 30, 2026 consisted primarily of (i) $192.4 million related to proportional recognition of the initial
$200.0 million opt-out payment received from Takeda, (ii) $27.4 million for ongoing development services, including post opt-out wind down services, and rusfertide clinical supplies provided by us under the Takeda Collaboration Agreement and other revenues, and (iii) a $50.0 million milestone earned from JNJ in Q1 2026 upon FDA approval of ICOTYDE.
License and collaboration revenue of
$5.5 million for second quarter of 2025 consisted of (i) $5.0 million related to the initial transaction price of the Takeda collaboration agreement for development services provided by us, and (ii) $0.5 million related to the proportional recognition of the $25 million milestone earned in Q1 2025 but receivable following completion of the VERIFY clinical study report. License and collaboration revenue of $33.9 million for the six months ended June 30, 2025 consisted of: (i) $23.4 million related to proportional recognition of the $25 million milestone earned in Q1 2025 but payable following completion of the VERIFY clinical study report, and (ii) $10.5 million allocated to development services provided by us under the agreement during the period.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™
(icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the
Interleukin-23 receptor. ICOTYDE, launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and
Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization.
Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda
Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its...line drug candidates and its clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Cautionary Note on
Financial statements
Income Statement
Three Months Ended — Second Quarter 2026 Financial Results (in thousands, except per share amounts)
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | |
|---|---|---|---|---|
| License and collaboration revenue | 213,475 | 5,546 | 269,843 | 33,867 |
| Research and development expense | 42,061 | 37,036 | 88,800 | 72,929 |
| General and administrative expense | 12,648 | 10,551 | 25,925 | 22,289 |
| Income tax expense | 2,265 | 172 | 763 | 172 |
| Net income (loss) | 162,849 | -34,771 | 166,632 | -46,426 |
| Basic earnings (loss) per share | 2.47 | -0.55 | 2.54 | -0.73 |
| Diluted earnings (loss) per share | 2.29 | -0.55 | 2.35 | -0.73 |
Income Statement
Three Months Ended — (Amounts in thousands except share and per share data)
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | ||
|---|---|---|---|---|---|
| License and collaboration revenue | 213,475 | 5,546 | 269,843 | 33,867 | |
| Operating expense: | Research and development (1) | 42,061 | 37,036 | 88,800 | 72,929 |
| Operating expense: | General and administrative (1) | 12,648 | 10,551 | 25,925 | 22,289 |
| Operating expense: | Total operating expense | 54,709 | 47,587 | 114,725 | 95,218 |
| Operating expense: | Income (loss) from operations | 158,766 | -42,041 | 155,118 | -61,351 |
| Operating expense: | Interest income | 6,429 | 7,406 | 12,305 | 14,979 |
| Operating expense: | Other (expense) income, net | -81 | 36 | -28 | 118 |
| Operating expense: | Income (loss) before income tax expense | 165,114 | -34,599 | 167,395 | -46,254 |
| Operating expense: | Income tax expense | 2,265 | 172 | 763 | 172 |
| Operating expense: | Net income (loss) | 162,849 | -34,771 | 166,632 | -46,426 |
| Operating expense: | Net income (loss) per share, basic | 2.47 | -0.55 | 2.54 | -0.73 |
| Operating expense: | Net income (loss) per share, diluted | 2.29 | -0.55 | 2.35 | -0.73 |
| Operating expense: | Weighted-average shares used to compute net income (loss) per share, basic | 65,935,769 | 63,510,537 | 65,514,150 | 63,238,682 |
| Operating expense: | Weighted-average shares used to compute net income (loss) per share, diluted | 71,007,011 | 63,510,537 | 70,818,718 | 63,238,682 |
Balance Sheet
December 31, — (In thousands) (in thousands)
| June 30, – 2026 | December 31, – 2025 | |
|---|---|---|
| Cash, cash equivalents and marketable securities | 849,451 | 646,002 |
| Working capital | 769,967 | 532,133 |
| Total assets | 885,544 | 668,188 |
| Deferred revenue | 9,659 | 9,550 |
| Accumulated deficit | -304,039 | -470,671 |
| Total stockholders' equity | 841,543 | 614,707 |
Full release
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements regarding potential revenue from the Company's collaborations with Johnson
& Johnson and Takeda, timing of regulatory actions and clinical trial completion, and advancement of the Company's discovery and clinical pipeline. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe,"
"may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone and royalty payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk
Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange
Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition, and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release.
We assume no obligation to update our forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors cdavis@lifesciadvisors.com
+1 212 915 2577
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies virginiaamann@ententeinc.com
+1 833 500 0061 ext 1
PROTAGONIST THERAPEUTICS,
INC.
Consolidated
Statements of Operations
(Amounts in thousands except share and per share data)
(1) Amount includes non-cash stock-based compensation expense.
Stock-based
Compensation
(In thousands)
PROTAGONIST THERAPEUTICS,
INC.
Selected Consolidated
Balance Sheet Data
(In thousands)